Popovits Kimberly J 4

What Happened

• Kimberly J. Popovits, a director of Rhythm Pharmaceuticals, was granted awards on April 1, 2026: 6,808 restricted stock units (RSUs) and 10,257 stock options. Both grants are reported as derivative awards at $0.00 (i.e., awarded, not purchased).
• The RSUs are contingent rights to receive one share each upon vesting; the RSUs vest 33% on each of April 1, 2027, 2028 and 2029 and have no expiration date. The stock options were also granted April 1, 2026 and vest in three substantially equal annual installments, subject to continued service.

Key Details

• Transaction date: April 1, 2026; Form filed April 3, 2026 (timely within the 2-business-day Form 4 deadline).
• Grants: 6,808 RSUs (F1/F2) and 10,257 stock options (F3); both reported at $0.00 (award/grant).
• Total potential securities awarded: 17,065.
• Shares owned after the transaction: not specified in the filing.
• Notable footnotes: F1 = each RSU converts to one share; F2 = RSU vesting schedule (33% annually Apr 1, 2027–2029); F3 = option vesting in three equal annual installments.
• Exercise price/strike for the options is not disclosed in the provided transaction lines.

Context

• RSUs represent a future right to receive shares at vesting (no immediate share transfer); options give the right to buy shares if and when vested and exercised. Neither is an immediate cash purchase or sale.
• Director equity awards are a common form of compensation intended to align interests with shareholders; they do not by themselves indicate the director is buying or selling stock in the open market.